In collaboration with:
Program Description:
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality worldwide, and complications arising from ASCVD have been associated with greater health care resource utilization as well as increased direct and indirect costs. Effective lipid management, centered on the reduction of LDL-C, is the cornerstone of secondary prevention; however, a substantial proportion of high-risk patients fall short of meeting guideline-recommended targets on statin monotherapy. This program is designed to equip managed care professionals and pharmacists with strategies to advance value-based hyperlipidemia care by utilizing evidence-based risk stratification tools and ensuring guideline adherence. The latest clinical trial data and expanded FDA indications for non-statin therapies as well as emerging LDL-C-lowering therapies will be discussed. Beyond pharmacotherapy, the session will address the logistical side of lipid management, focusing on navigating prior authorization and benefit design to ensure timely identification and treatment initiation among patients that may benefit from non-statin therapies.
Target audience: Managed Care Pharmacist
Type of activity: Application
Release date: May 26, 2026
Expiration date: August 23, 2026
Time to complete activity: 1.0 hour
Learner level: Foundational, Intermediate
Fee: Free
Educational
Objectives:
At the completion of this activity, participants will be able to:
- Factor data on the clinical burden of atherosclerotic cardiovascular disease into evidence-based risk-stratification and lipid-biomarker evaluation for patients who require early cardiovascular intervention
- Interpret updated clinical guideline recommendations discussing the progression, efficacy, and safety of established and emerging non-statin lipid-lowering therapies
- Identify population-health approaches to support high-risk patients, enhancing access to non-statin therapies and advancing value-based care through timely treatment
Steven Kheloussi, PharmD, MBA, FAMCP
Principal Consultant
Kheloussi Consulting, LLC
Wilkes-Barre, PA
Adjunct Professor of Pharmacy Practice
Wilkes University
Wilkes-Barre, PA
Accreditation Information
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number UAN. The activity is available for CE credit through June 23, 2027.
Instructions for Completing the Activity and Receiving CPE Credit
To
receive CPE credit, participants must complete the pretest, review the activity in
its entirety, complete the posttest, and complete the online activity
evaluation. After successful completion of the online activity evaluation, you
can submit your credit to CPE Monitor. You may view your credit within 48 hours
at www.mycpemonitor.net. All participants must request credit before the
activity expiration date. CE credit will not be issued after this date.
Disclosures
Steven Kheloussi, PharmD, MBA, FAMCP, has no relevant financial relationships with ineligible companies to disclose.
Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Liza Patel, PharmD, RPh; Macara Desai; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with ineligible companies to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated.
At least one anonymous peer reviewer has
been used as part of content validation and conflict resolution. The peer
reviewer has no relevant financial relationships with ineligible companies to
disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not
constitute any form of professional advice or referral. Discussions concerning
drugs, dosages, and procedures may reflect the clinical experience of the
author(s) or they may be derived from the professional literature or other
sources and may suggest uses that are investigational in nature and not
approved labeling or indications. Participants are encouraged to refer to
primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
Privacy Policy and Terms of Use Information: